ID: ALA1255817

Max Phase: Preclinical

Molecular Formula: C11H8O6

Molecular Weight: 236.18

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)Cc1cc(=O)oc2cc(O)c(O)cc12

Standard InChI:  InChI=1S/C11H8O6/c12-7-3-6-5(1-10(14)15)2-11(16)17-9(6)4-8(7)13/h2-4,12-13H,1H2,(H,14,15)

Standard InChI Key:  VZBNZFYHLQRFPS-UHFFFAOYSA-N

Molecule Features

Natural Product: Yes

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 236.18

Molecular Weight (Monoisotopic): 236.0321

AlogP: 0.83

#Rotatable Bonds: 2

Polar Surface Area: 107.97

Molecular Species: ACID

HBA: 5

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.21

CX Basic pKa:

CX LogP: 0.60

CX LogD: -2.97

Aromatic Rings: 2

Heavy Atoms: 17

QED Weighted: 0.53

Np Likeness Score: 0.54

References

1. Kato A, Kobayashi K, Narukawa K, Minoshima Y, Adachi I, Hirono S, Nash RJ..  (2010)  6,7-Dihydroxy-4-phenylcoumarin as inhibitor of aldose reductase 2.,  20  (19): [PMID:20805028] [10.1016/j.bmcl.2010.08.038]

2. Xia YL,Wang JJ,Li SY,Liu Y,Gonzalez FJ,Wang P,Ge GB.  (2021)  Synthesis and structure-activity relationship of coumarins as potent Mcl-1 inhibitors for cancer treatment.,  29  [PMID:33218896] [10.1016/j.bmc.2020.115851]

Source

Source(1):

• Scientific Literature